By Joanne Faulkner
The Court of Appeal ruled on Friday that the Competition Appeal Tribunal was wrong to remake a decision to fine Pfizer Ltd. and Flynn Pharma Ltd. £70 million ($93 million) for excessive pricing, finding that the process was tainted by procedural unfairness.
Read Full Article